News from actavis plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 24, 2014, 13:15 ET

Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension

 Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration...

Dec 24, 2014, 08:00 ET

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

 Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has...

Dec 22, 2014, 09:24 ET

Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Jonathon Kellerman has joined the Company as...

Dec 22, 2014, 09:00 ET

Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will...

Dec 19, 2014, 16:15 ET

XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults

 Actavis plc (NYSE: ACT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Dec 19, 2014, 09:00 ET

Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

 Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis,...

Dec 16, 2014, 07:30 ET

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition

 Actavis plc (NYSE: ACT) today announced the planned senior management team that will lead the global pharmaceutical company following the...

Dec 15, 2014, 15:11 ET

Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR

 Actavis plc (NYSE: ACT) today confirmed that it is filing an emergency appeal to the U.S. Court of Appeals for the Second Circuit seeking to...

Dec 11, 2014, 18:52 ET

Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR

 Actavis plc (NYSE: ACT) today confirmed that Judge Robert Sweet of the United States District Court for the Southern District of New...

Dec 10, 2014, 09:28 ET

Actavis Launches Generic Version of Celebrex®

Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Celebrex®  (celecoxib) 50 mg, 100 mg, 200 mg and...

Dec 05, 2014, 16:46 ET

Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam

 Actavis plc (NYSE: ACT) today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration...

Dec 01, 2014, 16:05 ET

Actavis Launches Generic Version of Intuniv®

 Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Intuniv® (guanfacine...

Nov 17, 2014, 09:15 ET
Actavis plc logo.

Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will...

Nov 17, 2014, 08:00 ET

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer

Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata...

Nov 13, 2014, 08:00 ET

Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients

 Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' Supplemental New...

Nov 10, 2014, 16:15 ET

Actavis Names Maria Teresa Hilado Chief Financial Officer

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Maria Teresa (Tessa) Hilado will join the Company,...

Nov 05, 2014, 06:45 ET

Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015

 Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will...

Nov 05, 2014, 06:30 ET

Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19

 Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014,...

Oct 31, 2014, 16:15 ET

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata

 Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted...

Oct 23, 2014, 08:00 ET

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent

 Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that...